

## **MEDICAL TIPS**

## **LIPONORM Tablets**

Issue X, No.38, 2023

Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.

Neilan T, et al. JAMA. 2023; 330(6): 528-536.

- Research suggests that patients on anthracycline-based chemotherapy for lymphoma may be associated with late cardiac effects, including heart failure.
- Statins may help preserve cardiac function in these patients as per clinical evidences.
- The present study was therefore conducted where patients prior to chemotherapy with anthracycline were randomized to Atorvastatin 40 mg/day (n=150) or placebo (n=150) for 12 months.
- Treatment with Atorvastatin led to reduction in left ventricular ejection fraction (LVEF) of ≥10% with incident heart failure rate being lesser than the placebo group.

Prophylactic Atorvastatin may lower the rate of cardiac dysfunction in patients who are at risk of developing cardiac problems due to anthracycline-based chemotherapy.

**\* \* \* \* \***